卵巢癌的遗传异质性表明需要个性化的治疗方法。目前，很少有 G 蛋白偶联受体 (GPCR) 被研究用于纳米药物的主动靶向，例如抗体偶联药物和载药纳米颗粒，这突显了开发个性化治疗的潜力被忽视。为了解决卵巢癌的遗传异质性，未来的个性化方法可能包括识别癌症活检中表达的独特 GPCR，并与个性化 GPCR 靶向纳米药物相匹配，以便在手术前、术中和术后向肿瘤组织输送致命药物。在此，我们报告了对公共核糖核酸测序 (RNA-seq) 基因表达数据的系统分析，从而优先考虑了 13 个 GPCR 作为在卵巢癌组织中频繁过度表达的候选者。随后，使用源自腹水和卵巢癌细胞系的原代卵巢癌细胞来确认所选 GPCR 的频繁基因表达。然而，在我们选择的样本中，表达水平显示出很高的变异性，因此支持并强调了未来开发个案个性化靶向方法的需要。© 2024。作者。

Genetic heterogeneity in ovarian cancer indicates the need for personalised treatment approaches. Currently, very few G-protein coupled receptors (GPCRs) have been investigated for active targeting with nanomedicines such as antibody-conjugated drugs and drug-loaded nanoparticles, highlighting a neglected potential to develop personalised treatment. To address the genetic heterogeneity of ovarian cancer, a future personalised approach could include the identification of unique GPCRs expressed in cancer biopsies, matched with personalised GPCR-targeted nanomedicines, for the delivery of lethal drugs to tumour tissue before, during and after surgery. Here we report on the systematic analysis of public ribonucleic acid-sequencing (RNA-seq) gene expression data, which led to prioritisation of 13 GPCRs as candidates with frequent overexpression in ovarian cancer tissues. Subsequently, primary ovarian cancer cells derived from ascites and ovarian cancer cell lines were used to confirm frequent gene expression for the selected GPCRs. However, the expression levels showed high variability within our selection of samples, therefore, supporting and emphasising the need for the future development of case-to-case personalised targeting approaches.© 2024. The Author(s).